SG11202113214QA - Tricyclic compounds - Google Patents
Tricyclic compoundsInfo
- Publication number
- SG11202113214QA SG11202113214QA SG11202113214QA SG11202113214QA SG11202113214QA SG 11202113214Q A SG11202113214Q A SG 11202113214QA SG 11202113214Q A SG11202113214Q A SG 11202113214QA SG 11202113214Q A SG11202113214Q A SG 11202113214QA SG 11202113214Q A SG11202113214Q A SG 11202113214QA
- Authority
- SG
- Singapore
- Prior art keywords
- optionally substituted
- compound
- alkyl
- unsubstituted
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962854597P | 2019-05-30 | 2019-05-30 | |
| PCT/US2020/034746 WO2020243199A1 (en) | 2019-05-30 | 2020-05-27 | Tricyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202113214QA true SG11202113214QA (en) | 2021-12-30 |
Family
ID=73552666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202113214QA SG11202113214QA (en) | 2019-05-30 | 2020-05-27 | Tricyclic compounds |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11136321B2 (https=) |
| EP (1) | EP3976618A4 (https=) |
| JP (1) | JP2022534501A (https=) |
| KR (1) | KR20220016177A (https=) |
| CN (1) | CN113906029A (https=) |
| AU (1) | AU2020282707B2 (https=) |
| BR (1) | BR112021023967A2 (https=) |
| CA (1) | CA3138938A1 (https=) |
| CL (1) | CL2021003139A1 (https=) |
| CO (1) | CO2021017202A2 (https=) |
| EA (1) | EA202192760A1 (https=) |
| IL (1) | IL287813A (https=) |
| MA (1) | MA56058A (https=) |
| MX (1) | MX2021014458A (https=) |
| PE (1) | PE20220427A1 (https=) |
| PH (1) | PH12021552953A1 (https=) |
| SG (1) | SG11202113214QA (https=) |
| TW (1) | TW202110845A (https=) |
| WO (1) | WO2020243199A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220000874A1 (en) * | 2019-05-30 | 2022-01-06 | Aligos Therapeutics, Inc. | Tricyclic compounds |
| TWI886184B (zh) * | 2019-12-10 | 2025-06-11 | 大陸商上海翰森生物醫藥科技有限公司 | 含吡唑多環類衍生物抑制劑、其製備方法和應用 |
| GB202103704D0 (en) * | 2021-03-17 | 2021-04-28 | Pathios Therapeutics Ltd | Compounds |
| EP4251625A4 (en) * | 2020-11-24 | 2024-10-09 | Aligos Therapeutics, Inc. | Tricyclic compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0701273D0 (en) * | 2007-01-24 | 2007-02-28 | Angeletti P Ist Richerche Bio | New compounds |
| WO2008157273A1 (en) * | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
| AU2013404035B2 (en) * | 2013-10-29 | 2017-04-20 | Medivir Ab | Quinazoline based respiratory syncytial virus inhibitors |
| CO2018009382A2 (es) | 2016-03-09 | 2018-09-20 | Univ Emory | Eliminación del virus de la hepatitis b con agentes antivirales |
| CN110066278B (zh) * | 2017-06-01 | 2021-06-08 | 广东东阳光药业有限公司 | 稠合三环类化合物及其在药物中的应用 |
-
2020
- 2020-05-27 CN CN202080040114.2A patent/CN113906029A/zh active Pending
- 2020-05-27 JP JP2021570378A patent/JP2022534501A/ja active Pending
- 2020-05-27 KR KR1020217042967A patent/KR20220016177A/ko not_active Ceased
- 2020-05-27 EA EA202192760A patent/EA202192760A1/ru unknown
- 2020-05-27 CA CA3138938A patent/CA3138938A1/en active Pending
- 2020-05-27 US US16/885,128 patent/US11136321B2/en active Active
- 2020-05-27 PE PE2021001952A patent/PE20220427A1/es unknown
- 2020-05-27 EP EP20812759.7A patent/EP3976618A4/en not_active Withdrawn
- 2020-05-27 WO PCT/US2020/034746 patent/WO2020243199A1/en not_active Ceased
- 2020-05-27 BR BR112021023967A patent/BR112021023967A2/pt not_active IP Right Cessation
- 2020-05-27 AU AU2020282707A patent/AU2020282707B2/en not_active Expired - Fee Related
- 2020-05-27 PH PH1/2021/552953A patent/PH12021552953A1/en unknown
- 2020-05-27 MA MA056058A patent/MA56058A/fr unknown
- 2020-05-27 MX MX2021014458A patent/MX2021014458A/es unknown
- 2020-05-27 SG SG11202113214QA patent/SG11202113214QA/en unknown
- 2020-05-29 TW TW109118090A patent/TW202110845A/zh unknown
-
2021
- 2021-11-03 IL IL287813A patent/IL287813A/en unknown
- 2021-11-25 CL CL2021003139A patent/CL2021003139A1/es unknown
- 2021-12-15 CO CONC2021/0017202A patent/CO2021017202A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020243199A1 (en) | 2020-12-03 |
| MA56058A (fr) | 2022-04-06 |
| EP3976618A4 (en) | 2023-01-04 |
| US11136321B2 (en) | 2021-10-05 |
| KR20220016177A (ko) | 2022-02-08 |
| PH12021552953A1 (en) | 2022-07-25 |
| JP2022534501A (ja) | 2022-08-01 |
| BR112021023967A2 (pt) | 2022-03-08 |
| EA202192760A1 (ru) | 2022-03-05 |
| PE20220427A1 (es) | 2022-03-29 |
| MX2021014458A (es) | 2022-01-06 |
| EP3976618A1 (en) | 2022-04-06 |
| CL2021003139A1 (es) | 2022-09-23 |
| CN113906029A (zh) | 2022-01-07 |
| AU2020282707A1 (en) | 2021-12-02 |
| US20200407361A1 (en) | 2020-12-31 |
| AU2020282707B2 (en) | 2025-06-19 |
| TW202110845A (zh) | 2021-03-16 |
| IL287813A (en) | 2022-01-01 |
| CO2021017202A2 (es) | 2022-01-17 |
| CA3138938A1 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202113214QA (en) | Tricyclic compounds | |
| JP2694535B2 (ja) | チアジアジノン化合物 | |
| CN106957282B (zh) | B型肝炎抗病毒剂 | |
| KR102085121B1 (ko) | 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도 | |
| SG181507A1 (en) | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors | |
| CN101050194B (zh) | 双环辛烷类衍生物、其制备方法及其在医药上的用途 | |
| CN110114071A (zh) | 含有取代的吡啶酮的三环化合物以及使用其的方法 | |
| JP2011068681A (ja) | 抗ウイルス物質としての置換５−カルボキシアミドピラゾールおよび置換［１，２，４］トリアゾール | |
| JP2022518456A (ja) | 置換多環式カルボン酸、その類似体、およびそれらの使用法 | |
| US11820773B2 (en) | Tricyclic compounds | |
| JP2021501178A (ja) | 虚血性脳卒中の治療のための芳香族スルホンアミド誘導体 | |
| WO2022087011A1 (en) | Bicyclic compounds | |
| JP2022505268A (ja) | Ｃｄｋ９活性を調節するための化合物、組成物、および方法 | |
| CN101528741A (zh) | 多环病毒抑制剂 | |
| DE60207755T2 (de) | Triazole als oxytocin-antagonisten | |
| JPH04305578A (ja) | ベンゾジアゼピン、その製造法、及び薬剤としての利用 | |
| US20230051483A1 (en) | Bicyclic compounds | |
| DE69321915T2 (de) | 3-Oxadiazolyl-1,6-naphthyridinderivate mit Affinität an die Benzodiazepin-Rezeptoren | |
| SI9300288A (sl) | Benzodiazepini | |
| KR20080031281A (ko) | 락탐을 함유하는 ｈｃｖ 억제제 | |
| US20220000874A1 (en) | Tricyclic compounds | |
| AU3497293A (en) | Benzodiazepinones and medicines containing them | |
| JP2002526449A (ja) | ラミブジンおよびアバカビルを含んでなる抗ウイルス性組合せ製剤 | |
| JP2002536448A (ja) | 治療用ヌクレオシド化合物 | |
| WO2021030278A1 (en) | Bicyclic compounds |